Efficacy of bevacizumab and chemotherapy in the first-line
treatment of metastatic colorectal cancer: broadening
KRAS-focused clinical view

J 2015

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS et. al.

Základní údaje

Originální název

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

Autoři

BENCSIKOVÁ, Beatrix (703 Slovensko, garant), Zbyněk BORTLÍČEK (203 Česká republika, domácí), Jana HALÁMKOVÁ (203 Česká republika), Lenka OSTRIZKOVA (203 Česká republika), Igor KISS (203 Česká republika), Bohuslav MELICHAR (203 Česká republika), Tomáš PAVLÍK (203 Česká republika, domácí), Ladislav DUŠEK (203 Česká republika, domácí), Dalibor VALÍK (203 Česká republika), Rostislav VYZULA (203 Česká republika) a Lenka ZDRAŽILOVÁ DUBSKÁ (203 Česká republika, domácí)

Vydání

BMC Gastroenterology, LONDON, BioMed Central, 2015, 1471-230X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.101

Kód RIV

RIV/00216224:14110/15:00084399

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1186/s12876-015-0266-6

UT WoS

000351720700001

Klíčová slova anglicky

Colorectal cancer; Angiogenesis inhibitors; Bevacizumab; KRAS; Biomarkers; Antineoplastic agents; Clinical practice

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 26. 10. 2017 14:58, Soňa Böhmová

Anotace

V originále

Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. Conclusion: KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients.

Citovat

BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS, Bohuslav MELICHAR, Tomáš PAVLÍK, Ladislav DUŠEK, Dalibor VALÍK, Rostislav VYZULA a Lenka ZDRAŽILOVÁ DUBSKÁ. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology. LONDON: BioMed Central, 2015, roč. 15, MAR 24 2015, s. "nestránkováno", 10 s. ISSN 1471-230X. Dostupné z: https://dx.doi.org/10.1186/s12876-015-0266-6.

@article{1315243,
   author = {Bencsiková, Beatrix and Bortlíček, Zbyněk and Halámková, Jana and Ostrizkova, Lenka and Kiss, Igor and Melichar, Bohuslav and Pavlík, Tomáš and Dušek, Ladislav and Valík, Dalibor and Vyzula, Rostislav and Zdražilová Dubská, Lenka},
   article_location = {LONDON},
   article_number = {MAR 24 2015},
   doi = {http://dx.doi.org/10.1186/s12876-015-0266-6},
   keywords = {Colorectal cancer; Angiogenesis inhibitors; Bevacizumab; KRAS; Biomarkers; Antineoplastic agents; Clinical practice},
   language = {eng},
   issn = {1471-230X},
   journal = {BMC Gastroenterology},
   title = {Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view},
   volume = {15},
   year = {2015}
}

TY  - JOUR
ID  - 1315243
AU  - Bencsiková, Beatrix - Bortlíček, Zbyněk - Halámková, Jana - Ostrizkova, Lenka - Kiss, Igor - Melichar, Bohuslav - Pavlík, Tomáš - Dušek, Ladislav - Valík, Dalibor - Vyzula, Rostislav - Zdražilová Dubská, Lenka
PY  - 2015
TI  - Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
JF  - BMC Gastroenterology
VL  - 15
IS  - MAR 24 2015
SP  - "nestránkováno"
EP  - "nestránkováno"
PB  - BioMed Central
SN  - 1471230X
KW  - Colorectal cancer
KW  - Angiogenesis inhibitors
KW  - Bevacizumab
KW  - KRAS
KW  - Biomarkers
KW  - Antineoplastic agents
KW  - Clinical practice
N2  - Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0% vs 23.8%; p = 0.001). We observed no difference in clinical outcome between hepatic and extrahepatic metastatic disease. Conclusion: KRAS mutation does not interfere with clinical benefit from first-line treatment with bevacizumab plus chemotherapy in mCRC patients.
ER  -

BENCSIKOVÁ, Beatrix, Zbyněk BORTLÍČEK, Jana HALÁMKOVÁ, Lenka OSTRIZKOVA, Igor KISS, Bohuslav MELICHAR, Tomáš PAVLÍK, Ladislav DUŠEK, Dalibor VALÍK, Rostislav VYZULA a Lenka ZDRAŽILOVÁ DUBSKÁ. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. \textit{BMC Gastroenterology}. LONDON: BioMed Central, 2015, roč.~15, MAR 24 2015, s.~''nestránkováno'', 10 s. ISSN~1471-230X. Dostupné z: https://dx.doi.org/10.1186/s12876-015-0266-6.

Podrobný výpis o publikaci